Figure 8.

CD8⁺ T-cell response induced by the nanostructured formulation protects against Lm-OVA infection. C57BL/6 mice were immunized on day 0 with OVA/CpG-ODN, OVA/CpG-ODN/Coa-ASC16 or CpG-ODN/Coa-ASC16. Seven days later, immunized and non-immunized mice were intravenously infected with 1 × 10⁵ CFU of Lm-OVA. Two days after infection, mice were euthanized for liver and spleen extraction. (A) Percentage of SIINFEKL-K^b tetramer⁺ CD8⁺ T-cells in spleen. (B) Total number of SIINFEKL-K^b tetramer⁺ CD8⁺ T-cells/spleen. (C–E) CD8⁺ T-cell cytokine production from splenocytes after in vitro stimulation with SIINFEKL peptide. Multiparameter flow cytometry was used to determine (C) percentage and (D) total number of CD8⁺ T-cells expressing each of the seven possible combinations of IFN-γ, TNF-α, and CD107a, (E) the fraction of the total CD8⁺ T-cell response comprising cells expressing each of the seven combinations of IFN-γ, TNF-α and CD107a. For gating strategy and representative flow cytometry data, see Supplementary Figure 4. (F) Bacterial load in liver. The data show the mean ± SEM of individual values (3–4 mice/treatment group in each experiment) and are representative of two independent experiments performed. n.s., not significant, ^*p < 0.05, ^**p < 0.01, ^***p < 0.001.